U.S. Biotech Stock News

Investors may be wondering if Signet Jewelers at around US$84 is still offering value, or if the easy money has already been made. The stock has pulled back recently, with a 5.6% decline over the last 7 days and a 12.6% decline over the last 30 days, even though the 1-year return sits at 45.1% and the 5-year return at 55.8%. This recent volatility comes after a period where Signet's share price performance over 3 years and 5 years has been positive overall. This can change how the market...

FedEx (NYSE:FDX) presented the FedEx Global Possibilities Award at Junior Achievement Africa's Company of the Year competition, recognizing a student enterprise focused on reducing vehicle emissions. The company also hosted a career readiness webinar for Marine Corps family scholars, aimed at supporting their transition into the workforce. These initiatives highlight FedEx's recent focus on community impact, sustainability and workforce development alongside its core logistics...

In recent months, KKR has outlined an ambitious growth plan and record US$129.00 billion fundraising, agreed to sell CoolIT Systems to Ecolab for US$4.75 billion, moved to acquire bakery chain Nothing Bundt Cakes for over US$2.00 billion including debt, and backed large-scale data center developments on US Army bases through its CyrusOne stake. Together, these moves highlight how KKR is recycling capital from a very large tech-infrastructure exit into new digital infrastructure and consumer...

Recent performance context Without a specific headline event to point to, ProPetro Holding (PUMP) still stands out for investors watching performance. The stock shows positive returns over the past week, month and past 3 months, alongside double digit annual revenue and net income growth. See our latest analysis for ProPetro Holding. With the share price at US$14.69, ProPetro’s recent trend is firmly upward, with a 30 day share price return of 21.1% and a 90 day share price return of 58.6%,...

Recent Performance Snapshot for Main Street Capital Main Street Capital (MAIN) has drawn attention after a weak stretch, with the share price reflecting a 2.6% decline over the past day and double digit drops over the past month and past 3 months. For investors tracking income focused financials, these returns sit alongside reported annual revenue of US$566.391 million and net income of US$493.398 million, providing a reference point for a closer look at the stock. See our latest analysis for...

Earlier in March 2026, analysts including Wells Fargo and Maxim updated their views on Vertex Pharmaceuticals, highlighting the company’s expanding pipeline in areas such as generalized myasthenia gravis and its efforts to diversify beyond cystic fibrosis. This renewed analyst focus underscores how expectations around Vertex’s next wave of therapies, especially in autoimmune and rare diseases, are increasingly central to the company’s long-term story. We’ll now explore how this heightened...

Why Resideo Technologies is on investors’ radar today Resideo Technologies (REZI) has drawn attention after a recent pullback, with the stock down about 14% over the past month and 7% over the past 3 months, despite a strong 1 year total return near 87%. See our latest analysis for Resideo Technologies. The recent 1 month share price return of about a 14% decline, on top of a 7% decline over 3 months, sits in sharp contrast to the 1 year total shareholder return of roughly 87%. This suggests...

Tidewater (NYSE:TDW) director Darron M. Anderson will step down from the board at the 2026 Annual Meeting. The board will shrink from eight to seven members after Anderson’s planned departure. Anderson is not seeking reelection and is expected to serve out his current term on the Audit and Safety & Sustainability Committees. The company states his decision is not related to any disagreement with management or board policies. Tidewater comes into this board change with its shares at $82.4...

Stoke Therapeutics (STOK) is back in focus after reporting full year 2025 results, with sales of US$184.42 million and a sharply smaller net loss, alongside pipeline progress for STK-002 and zorevunersen. See our latest analysis for Stoke Therapeutics. At a share price of US$32.85, Stoke Therapeutics has given investors a very large 1 year total shareholder return of 355.62%. The 30 day share price return of a 9.78% decline suggests some recent momentum has cooled after a strong run helped by...

Palomar Holdings stock: recent performance snapshot Palomar Holdings (PLMR) has drawn investor attention after a recent pullback, with the share price at $116.83 and negative returns over the past month, past 3 months, year to date, and past year. See our latest analysis for Palomar Holdings. The recent 1 day share price return of a 3.68% decline and 30 day share price return of a 5.56% decline contrast with a 3 year total shareholder return of 111.65%. This suggests that longer term momentum...

The leak of Anthropic's Claude Mythos model has put renewed pressure on application software stocks, and Atlassian (TEAM) was caught in this AI scare trade as investors reassessed sector margins. See our latest analysis for Atlassian. Beyond the latest AI jitters, Atlassian’s 1-day share price return of 4.4% and 7-day return of 11.7% sit within a much steeper 90-day share price decline of 60.3% and a 1-year total shareholder return of 70.1%. This signals pressure that has been building for...

Context for the Recent Move in Amicus Therapeutics (FOLD) Recent trading in Amicus Therapeutics (FOLD) puts the spotlight back on how investors are weighing its rare disease portfolio against current financial metrics, including revenue, profitability, and multi year total returns. See our latest analysis for Amicus Therapeutics. At a share price of US$14.41, recent trading has been fairly muted over days and weeks. However, the 1 year total shareholder return of 70.94% and 5 year total...

Recent share performance and business snapshot With no single event driving headlines, Chubb (CB) has still drawn attention after a recent share pullback. This has invited investors to reassess the insurer’s US$124.2b market value and diversified global operations. See our latest analysis for Chubb. Chubb’s recent 6.4% one month share price pullback contrasts with a 2.9% year to date share price gain and a 9.0% one year total shareholder return. This points to moderating short term momentum...

If you are wondering whether Nova's share price still offers value after a big run, or if you may be late to the story, this breakdown can help frame what the current market price might be implying. Nova closed at US$440.72, with returns of 26.9% year to date and 136.4% over the last year. Over the last 7 days and 30 days, the stock has seen more muted moves of a 5.3% decline and a 0.4% gain, respectively. Recent coverage around Nova has focused on its role in the semiconductor equipment...

Market reaction and governance changes set the stage Entegris (ENTG) quickly came into focus after sector wide selling linked to concerns over Google’s TurboQuant algorithm and its potential effect on memory demand, just as shareholders prepare to vote on governance changes. See our latest analysis for Entegris. At a share price of US$113.59, Entegris has seen a 30 day share price return of a 14% decline. However, its 90 day share price return of 32.17% and 1 year total shareholder return of...

Merck (MRK) has drawn attention after recent share price moves, with the stock showing mixed short term performance while still reflecting longer term gains that may prompt investors to reassess risk and return expectations. See our latest analysis for Merck. The recent 7 day share price return of 4.8% comes after a softer 30 day share price return of 3.4%, while the 1 year total shareholder return of 38.9% suggests momentum has been building over a longer horizon. If Merck’s recent moves...

Why Catalyst Pharmaceuticals (CPRX) is Back on Investors’ Radar Catalyst Pharmaceuticals (CPRX) has drawn attention after a mixed stretch in the stock, with a small month gain but a decline over the past 3 months and past year. This has prompted fresh interest in its fundamentals. See our latest analysis for Catalyst Pharmaceuticals. At a share price of US$23.40, Catalyst’s recent 1 day share price return of a 3.51% decline and 7 day gain of 2.68% contrast with a softer 1 year total...

Wondering if Deere at US$566.64 still offers value, or if most of the opportunity is already priced in. The stock's recent returns show a mixed picture, with a 1.2% gain over 7 days, a 10.0% decline over 30 days, and longer term returns of 21.4% year to date and 23.4% over 1 year. Recent news coverage has focused on Deere's role as a major machinery and equipment provider, which often puts the stock in the spotlight when investors reassess exposure to industrial and capital goods names. This...

This article examines whether United Parcel Service is currently a bargain or a value trap at its recent share price by exploring what the market price might be implying about the stock. The shares recently closed at US$94.80, with returns of a 1.1% decline over 7 days, an 18.2% decline over 30 days, a 6.2% decline year to date, a 7.6% decline over 1 year, a 42.8% decline over 3 years, and a 31.4% decline over 5 years, which may have influenced how investors think about both opportunity and...

Shareholders have filed a proposal asking Archer-Daniels-Midland to disclose pesticide use data within its regenerative agriculture program. The proposal will be voted on at the upcoming annual general meeting. ADM has recommended that investors vote against the measure in its meeting materials. NYSE:ADM, recently trading at $72.23, has seen a 22.3% return year to date and a 56.2% return over the past year. The stock also shows a 44.1% return over five years, which keeps it on the radar for...

Why Farmers National Banc (FMNB) is on investors’ radar Farmers National Banc (FMNB) has attracted attention after recent share price moves, with the stock down about 5% over the past 3 months but posting a roughly 4% total return over the past year. See our latest analysis for Farmers National Banc. The recent 1-day share price return of a 1% decline contrasts with a 7-day share price return of 2.3%. The 1-year total shareholder return of 4.1% points to modest but positive longer term...

In March 2026, NetApp announced a series of alliances and product launches, including new cyber resilience partnerships with Commvault and Elastio, next-generation EF50 and EF80 storage systems, and its NVIDIA co-engineered NetApp AI Data Engine to support AI, HPC, and hybrid cloud workloads. Together these moves expand NetApp’s role as a provider of integrated, AI-aware data infrastructure and ransomware recovery capabilities across on-premises and cloud environments, addressing...

Kinsale Capital Group recently reported that its net premiums earned expanded by 21.2% annually over the last two years, reflecting robust demand for its specialty insurance coverage serving higher-risk, hard-to-place customers that many traditional carriers avoid. What stands out is that earnings per share grew at a very large annual rate over the past five years, outpacing revenue gains and indicating that new business written in this niche segment has been highly profitable and...

Byrna Technologies (BYRN) has drawn fresh attention after appointing long time commercial leader Luan Pham as President, a move that highlights the company’s focus on execution in less lethal personal defense. See our latest analysis for Byrna Technologies. Despite Pham’s expanded remit and the upcoming presentation at the Roth Conference, recent share price momentum has been weak, with a 30 day share price return of 31.14% and a 1 year total shareholder return of 48.39%. However, the 3 year...